Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
CASI Pharmaceuticals, Inc. CASI
$2.52
+$0.01 (0.40%)
На 18:00, 12 мая 2023
+376.19%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
33570180.00000000
-
week52high
6.80
-
week52low
1.45
-
Revenue
43107000
-
P/E TTM
-3
-
Beta
0.42595100
-
EPS
-2.83000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 12:30
Описание компании
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 15 авг 2022 г. |
| BTIG | Buy | Buy | 03 июн 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 16 мая 2022 г. |
| BTIG | Buy | 18 мая 2021 г. | |
| HC Wainwright & Co. | Buy | Buy | 14 мая 2021 г. |
| BTIG | Buy | Buy | 16 ноя 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 15 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Huang James | A | 371517 | 33300 | 08 сент 2022 г. |
| Zukiwski Alexander A | A | 3000 | 3000 | 07 сент 2022 г. |
| Huang James | A | 338217 | 3111 | 07 сент 2022 г. |
| Huang James | A | 335106 | 19162 | 06 сент 2022 г. |
| Huang James | A | 315944 | 400 | 02 сент 2022 г. |
| Huang James | A | 315544 | 11821 | 01 сент 2022 г. |
| Huang James | A | 303723 | 24975 | 31 авг 2022 г. |
| Huang James | A | 278748 | 39527 | 26 авг 2022 г. |
| Huang James | A | 239221 | 5000 | 24 авг 2022 г. |
| Huang James | A | 234221 | 40000 | 23 авг 2022 г. |
Новостная лента
Casi Pharmaceuticals to run clinical trial for multiple myeloma drug in China
Market Watch
06 янв 2023 г. в 08:42
Shares of Casi Pharmaceuticals Inc. CASI, +3.63% were up 10% in premarket trading on Friday after the company said China will allow a Phase 1 clinical trial evaluating a multiple myeloma drug developed by the privately held Cleave Therapeutics. The study is expected to start this year.
CASI Pharmaceuticals, Inc. (CASI) Reports Q3 Loss, Lags Revenue Estimates
Zacks Investment Research
14 ноя 2022 г. в 09:47
CASI Pharmaceuticals, Inc. (CASI) delivered earnings and revenue surprises of 25.49% and 1.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ALJ Regional Hldgs (NASDAQ:ALJJ), CASI Pharmaceuticals (NASDAQ:CASI) – $2.2 Million Bet On Terns Pharmaceuticals? Check Out These 4 Penny Stocks Insiders Are Buying
Benzinga
09 сент 2022 г. в 10:32
The Dow Jones closed higher by around 193 points on Thursday. Investors, meanwhile, focused on some notable insider trades.
CASI Pharmaceuticals And 2 Other Stocks Under $4 Insiders Are Aggressively Buying
Benzinga
29 авг 2022 г. в 08:58
The Dow Jones tumbled by over 1,000 points on Friday. Investors, meanwhile, focused on some notable insider trades.
CASI Pharmaceuticals, Inc. (CASI) CEO Wei-Wu He on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
12 авг 2022 г. в 12:28
CASI Pharmaceuticals, Inc. (NASDAQ:CASI ) Q2 2022 Earnings Conference Call August 12, 2022 8:00 AM ET Company Participants Wei Zhang – Vice President Wei-Wu He – Chairman and Chief Executive Officer Alex Zukiwski – Executive Vice President and Chief Medical Officer Larry Zhang – President Rui Zhang – Vice President-Business Development Conference Call Participants Leland Gershell – Oppenheimer Sean Lee – H.C. Wainwright Operator Good day everyone and welcome to the CASI Pharmaceuticals' Second Quarter 2022 Earnings Conference Call.